Trump signs executive order directing FDA to review psychedelics designated as breakthrough therapy drugs

President Donald Trump signed an executive order directing the FDA to expedite the review of psychedelics designated as breakthrough therapy drugs. The order aims to accelerate access to experimental treatments for severe mental illness and depression, particularly for veterans.